glp-1 receptor agonists and sglt2 inhibitors Use of Among Patients with Type 1 Diabetes: A Nationwide Register-Based Cohort Study Use of GLP-1 Receptor Agonists
Description
Another systematic review of randomized trials found that muscle-related indices often exceeded the usual benchmark of about 25% of weight loss coming from fat-free mass
Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health
The future of weight loss medication is about to change dramatically
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide 1 (GLP-1), which ...
Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)
